Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.
Bottom Line: In addition, ASKP1240 did not destabilize platelet thrombi under physiological high shear conditions while mouse anti-human CD154 mAb (mu5C8) did.And ASKP1240 itself did not activate platelet and endothelial cells.The immunosuppressive effect was well correlated with the CD40 receptor saturation.
Affiliation: Development Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The constant region of ASKP1240 is converted to IgG4 to reduce ADCC and CDC activities that might injure CD40 positive cells (i.e. B cells, monocytes, platelet, endothelial cells, etc.). One hundred micrograms per milliliter of ASKP1240 IgG4 did not induce CD40 expressing cell lysis via ADCC and CDC activity in contrast with rituximab and IgG1 version of ASKP1240 (Figure 1).
Affiliation: Development Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan.